title: Translational research in glioblastoma multiforme: molecular criteria for patient selection.
abstract: In spite of the dismal outcome of glioblastoma multiforme (GBM), we are in a position to provide a ray of hope to patients and families. Methylation of MGMT in tumor occurs in approximately a third of patients and predicts meaningful response and survival to adjuvant radiotherapy plus temozolomide. Limited access to tumor tissue in some patients could be circumvented by examining MGMT methylation in circulating serum DNA, although this approach needs to be validated. Molecular signatures are also promising prognostic and predictive markers, and clinical trials should be carried out to validate their use in the selection of patients for specific targeted therapies. Gene expression by quantitative PCR of key components of these molecular signatures could pave the way for easy identification of different subgroups of patients. Translational clinical trials are warranted in order to detect the subgroups of patients resistant to radiotherapy who may derive benefit from novel therapies, including antiangiogenic drugs.
authors.affiliation: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, s/n, 08916 Barcelona, Spain. rrosell@ico.scs.es
authors.forename: Rafael
authors.initials: R
authors.lastname: Rosell
authors.forename: Ramon
authors.initials: R
authors.lastname: de Las Peñas
authors.forename: Carme
authors.initials: C
authors.lastname: Balaña
authors.forename: Mariacarmela
authors.initials: M
authors.lastname: Santarpia
authors.forename: Fernanda
authors.initials: F
authors.lastname: Salazar
authors.forename: Itziar
authors.initials: I
authors.lastname: de Aguirre
authors.forename: Noemi
authors.initials: N
authors.lastname: Reguart
authors.forename: Salvador
authors.initials: S
authors.lastname: Villa
authors.forename: Jia
authors.initials: J
authors.lastname: Wei
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Ramirez
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Molina
authors.forename: Santiago
authors.initials: S
authors.lastname: Ramon y Cajal
authors.forename: David
authors.initials: D
authors.lastname: Jablons
authors.forename: Miquel
authors.initials: M
authors.lastname: Taron
mesh_terms: D016543:Central Nervous System Neoplasms / Q000209:etiology / Q000235:genetics* / Q000503:physiopathology / Q000628:therapy; D015254:DNA Modification Methylases / Q000235:genetics; D045643:DNA Repair Enzymes / Q000235:genetics; D004721:Endoplasmic Reticulum / Q000502:physiology; D000091342:Endoplasmic Reticulum Chaperone BiP; D005909:Glioblastoma / Q000209:etiology / Q000235:genetics* / Q000503:physiopathology / Q000628:therapy; D006360:Heat-Shock Proteins / Q000235:genetics; D006801:Humans; D018832:Molecular Chaperones / Q000235:genetics; D018579:Patient Selection; D015398:Signal Transduction; D013234:Stem Cells; D051742:Transcription Factor CHOP / Q000235:genetics; D025521:Tumor Suppressor Proteins / Q000235:genetics; D051153:Wnt Proteins / Q000502:physiology
chemical_list: C497249:DDIT3 protein, human; D000091342:Endoplasmic Reticulum Chaperone BiP; D006360:Heat-Shock Proteins; D018832:Molecular Chaperones; D025521:Tumor Suppressor Proteins; D051153:Wnt Proteins; D051742:Transcription Factor CHOP; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes